NUSHU Professional Interviews Initiated
In the past 6 months due to the project, the first batch of interviews for NUSHU, 7 professionals (2 physiatrists, 2 neurologists, 2 physiotherapists, and 1 occupational therapist) commenced.
E!1470 NUSHU R
E!1470 NUSHU R is our latest European project in collaboration with DeepBlue and EBRI (European Brain Research Institute by Rita Levi-Montalcini). E!1470 NUSHU R is an Eureka Eurostars project running for 2 years starting September 2022. We are looking forward to a successful collaboration with our Italian partners and cannot wait to share more updates on the project’s outcome with the world.
E!1470 NUSHU R is a Eureka Eurostars project. Eurostars is the largest international funding program for SMEs wishing to collaborate on R&D projects that create innovative products, processes, or services for commercialization. The goal of this project is to bring to market a wearable, at-home gait rehabilitation system that will aid stroke survivors in their recovery. The system is based on NUSHU smart shoes, with integrated sensors and real-time processing functionality that provide immediate feedback to patients. The system allows remote monitoring by measuring the ambulatory activity and provides rehabilitation exercises with real-time biofeedback.
- PUBLIC/PRIVATE INVESTMENT SINCE 2014
- 1.75B€
- PROJECT PARTNERS FORM LONG-TERM RELATIONSHIPS
- 84%
- PARTICIPANTS REACH NEW MARKETS
- 45%
Eureka Eurostars project in numbers:
Magnes AG
Magnes AG (Main partner): Magnes is a spinoff of the Institute of Robotics and Intelligent Systems of ETH Zurich. Magnes has developed a disruptive real-life-monitoring solution to analyze walk patterns of patients with neurological disorders. It is the only solution to give direct vibrotactile biofeedback to patients. Using smart sensors embedded in sneaker-like shoes it collects data while the patient is walking or doing daily activities. Magnes AI processes the data to generate automatic reports and provide the patient with direct feedback on their gait or warn/prevent situations like falling. The technology can change the way clinical trials are performed today and improve efficacy by enabling data-driven therapy through tailored medication dosage.
European Brain Research Institute (EBRI) Rita Levi-Montalcini
Established in 2002, by the will of Nobel Prize winner Rita Levi-Montalcini, EBRI addresses the need for a center in Europe where fundamental research on the brain can be conducted with the aim of identifying new therapeutic strategies for neurodegenerative diseases such as Alzheimer's and other serious disorders of the nervous system. The goal of the European Brain Research Institute is to study the biological basis of the higher functions of the mammalian brain: the relationships between mind and brain and the mechanisms of memory. Today, there are technologies that allow the brain to be studied at every level of its complexity and EBRI will utilize new technologies such as those provided by genetics, molecular biology, neurophysiology, cellular and molecular imaging, computer sciences, and the study of behavior and, above all, emerging genomic and proteomic technologies.
European Brain Research Institute (EBRI) Rita Levi-Montalcini
Established in 2002, by the will of Nobel Prize winner Rita Levi-Montalcini, EBRI addresses the need for a center in Europe where fundamental research on the brain can be conducted with the aim of identifying new therapeutic strategies for neurodegenerative diseases such as Alzheimer's and other serious disorders of the nervous system. The goal of the European Brain Research Institute is to study the biological basis of the higher functions of the mammalian brain: the relationships between mind and brain and the mechanisms of memory. Today, there are technologies that allow the brain to be studied at every level of its complexity and EBRI will utilize new technologies such as those provided by genetics, molecular biology, neurophysiology, cellular and molecular imaging, computer sciences, and the study of behavior and, above all, emerging genomic and proteomic technologies.
Deep Blue
Deep Blue is an Italian company, founded in 2001, that specializes in research and consulting on human-centered design and validation in transport, manufacturing, healthcare, and environment. Its mission is to help organizations innovate by analyzing problems and procedures, designing tailored solutions, and validating them in the field. They provide consultancy in human factors, safety, security, and sustainability, as well as professional training. It has gained an international reputation due to its extensive high-quality contribution to the field of aviation and air traffic control. They are the first SME to participate in a number of projects in safety and aviation under H2020. Deep Blue served the European Commission, Eurocontrol, and SESAR Joint Undertaking, among other EU bodies.
Latest news
To stay informed about our project's progress and important events, make sure to check for the latest news updates.
NUSHU R Project Kickoff Meeting
From October 26 to October 27 the NUSHU R kickoff meeting took place at Magnes HQ, in Zurich, Switzerland.
September 1st start of the project
The project officially commenced on September 1st, marking the beginning of an exciting journey. The team is ready to tackle the challenges ahead and bring the project to fruition.